Biotechnology

Windtree Therapeutics

Windtree Therapeutics released FY2025 Q3 earnings on November 19, 2025 (EST), actual revenue USD 0 (forecast USD 3.2 M), actual EPS USD -1.0848 (forecast USD -53.9999)

Windtree Therapeutics released FY2025 9 Months Earnings on November 19 (EST), with actual revenue of USD 0 and EPS of USD -8.7762

Windtree Therapeutics released FY2025 Semi-Annual earnings on August 19 (EST), actual revenue USD 0, actual EPS USD -6.6683

Windtree Therapeutics released FY2025 Q2 earnings on August 19 (EST), actual revenue USD 0 (forecast USD 3 M), actual EPS USD -3.0586 (forecast USD -98.9999)

Windtree Therapeutics Inc terminates SEISMIC-C clinical study

Windtree Therapeutics Announces No New Safety Signals in ISTAROXIME Phase 2 Interim Analysis

Windtree Therapeutics Secures $60 Million Financing for BNB Treasury Strategy

Windtree Therapeutics Inc. Issues Convertible Notes and Warrants

Windtree Therapeutics ISTAROXIME Receives US Patent

Windtree Therapeutics Completes Recruitment of 20 Patients in SEISMIC C Study

Windtree Therapeutics Partners with Overseas Manufacturer to Cut Contraceptive Gel Manufacturing Costs

Windtree Receives Deficiency Letter from NASDAQ

Windtree Therapeutics Plans to Acquire Titan Environmental Services for $35 Million

Windtree Therapeutics Inc Acquires Titan Environmental Services

Windtree Announces Mid-Term Results of Istaroxime Phase II Study to be Released

Windtree Therapeutics released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 2.2 M), actual EPS USD -4.6327 (forecast USD -179.9998)

Windtree Therapeutics Reports Q1 2025 Earnings

Windtree Therapeutics Showcases New Compound Data for Heart Failure Treatment

Windtree Therapeutics raises $2.5m through private placement of D-series convertible preferred stock

Windtree Therapeutics released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.3959 (forecast USD -39)

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

WHWK

WINT

Sidewinder Therapeutics has raised $137 million in a Series B funding round led by Novartis and OrbiMed to advance its bispecific antibody-drug conjugates (ADCs) to clinical trials. The funds will support the development of three bispecific ADCs, with plans to file an investigational new drug application for the lead asset, SWT012, by the end of 2026. The company aims to target solid tumors and capitalize on the growing investor interest in bispecific ADCs, which are seen as a potential breakthrough in cancer treatment.

Pharmaceutical Technology

Whitehawk Therapeutics

NOVARTIS AG

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

SPDR S&P Biotech

VanEck Biotech ETF

iShares US Pharma

iShares Global Healthcare

ORIC Pharmaceuticals

Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic

Windtree Therapeutics Delays Filing of Annual Report

Tip Ranks

Windtree Therapeutics Delays Filing of Annual Report

WTRE

GQRE

XLRE

SCHH

REET

CommLoan, a commercial real estate lending technology company, has received nationwide regulatory approval to operate in all 50 states. This expansion allows the company to enhance its AI-powered commercial lending marketplace and support transactions across state lines. Additionally, CommLoan plans a reverse merger with Windtree Therapeutics to access public markets. The company has also strengthened its leadership team to support growth in technology, operations, finance, and marketing. CommLoan aims to modernize commercial mortgage lending through its proprietary platform, CUPID™, connecting borrowers with active lenders nationwide.

prnewswire

WisdomTree New Economy Real Estate Fund

iShares US Real Estate ETF

FlexShares Glbl Quality Real Estate ETF

Real Est Select Spdr

SPDR Dow Jones Global Real Estate ETF

Vanguard Real Estate ETF

Schw Us Reit

iShares Global REIT

08:02 ETCommLoan Achieves Nationwide Regulatory Approval Across All 50 States

BNB coin price surged by 3.5% to over $715 after Windtree Therapeutics announced a $200M BNB-focused crypto treasury strategy. Windtree, a Nasdaq-listed biotech firm, plans to diversify its financial portfolio by integrating BNB into its treasury. The announcement, along with BNB Chain's network upgrades, has bolstered market sentiment, pushing BNB's market cap to over $104 billion.

Invezz

BNB coin price jumps following Windtree Therapeutics’ $200M BNB Treasury launch

Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to ...

GlobeNewswire

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company

Windtree Therapeutics(WINT.US)

Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic

Windtree Therapeutics Delays Filing of Annual Report

08:02 ETCommLoan Achieves Nationwide Regulatory Approval Across All 50 States

BNB coin price jumps following Windtree Therapeutics’ $200M BNB Treasury launch

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company